Gilead Sciences News

Gilead Sciences is a multi-billion dollar biopharmaceutical company that develops medicines for a range of diseases. It is research based, so to stay up-to-date with that research, and to keep track of the performance of the company along with other issues, sign up for the Wiser Gilead Sciences news email. The drugs that Gilead Services produces treat conditions like HIV/AIDS, liver disease, cancer, cardiovascular and respiratory conditions. The company was founded in 1987 and is based in California. The president and chief executive officer is John Martin. It has about 7,000 employees and is ranked as one of the top drug companies in the US with sales in 2013 of over $11 billion. Its hepatitis-C drug, Sovaldi, is predicted to sell well, plus it is expected to continue its expansion through acquisitions. This is in addition to new drugs that the company is developing. The Gilead Sciences news email from Wiser is the best way to get the latest news and information on the company. It is free, so register today.

Recent Gilead Sciences News Coverage
 
Your Weekly Recommendations Monday, May 29, 2017
 
Recommended for you
Don Rumsfeld Talks NATO, the Trump Cabinet and “Rabid” Trump Hate With Hugh Hewitt (FULL AUDIO)
Red State • Streiff
California Public Employees Union Pensions are Huge Hypocrites on Drug Prices
Red State • Dan Spencer
Trump Finds a Defender for His NATO Performance in Donald Rumsfeld (VIDEO)
Red State • Susan Wright
Lupin Plunges After Warning U.S. Drug Sales May Extend Drop
Bloomberg • Ari Altstedter
How To Double Your Money On A 6% Up Move In Gilead Sciences
Seeking Alpha • Giovanni Dimauro
The No. 1 Stock In The World (Revisited) - Apple Up, Realty Income Down
Seeking Alpha • Mike Nadel
Gilead's Dividend Stream Is Undervalued
Seeking Alpha • Abba's Aces
Cramer's lightning round: I've got a message for the struggling Gilead Sciences
CNBC
Gilead Sciences' (GILD) Presents at Bank of America Merrill Lynch Healthcare Broker Conference Call (Transcript)
Seeking Alpha
Vantage Point - Are Charities The Best Way To Pay For Costly Drugs?
Seeking Alpha • E.P. Vantage
 
Recommended for You
Gilead Sciences, Politics & Policy
Don Rumsfeld Talks NATO, the Trump Cabinet and “Rabid” Trump Hate With Hugh Hewitt (FULL AUDIO)
Red StateStreiff
Earlier today Hugh Hewitt (full disclosure*, Hugh Hewitt is part of Salem Media Group which also owns RedState) interviewed former Defense Secretary Donald Rumsfeld. This is the full audio of the interview: Obviously, the main topic of discussion was the Trump administration....
Share
AARP, Abbott Laboratories
California Public Employees Union Pensions are Huge Hypocrites on Drug Prices
Red StateDan Spencer
Two huge California public employee union pension programs are trying to eat their cake and profit from it too. They are helping to make a stink out of drug prices, even as those same drug prices are helping to prop up their...
Share
Gilead Sciences, Politics & Policy
Trump Finds a Defender for His NATO Performance in Donald Rumsfeld (VIDEO)
Red StateSusan Wright
The New York Times ripped President Trump’s NATO speech, calling it “embarrassing.” That’s the expected line from the Times, and more often than not – ME. Just to be completely honest, it’s not so much about the NATO speech, but just the...
Share
Accounting, Biotechnology
Lupin Plunges After Warning U.S. Drug Sales May Extend Drop
BloombergAri Altstedter
Lupin Ltd. fell to its lowest point in almost three years after warning that its U.S. revenue may extend declines over the coming year after India’s second-largest drug maker lost exclusive rights to sell generic versions of a pair of blockbuster diabetes...
Share
Gilead Sciences, Health Finance
How To Double Your Money On A 6% Up Move In Gilead Sciences
Seeking AlphaGiovanni Dimauro
Summary Gilead trading at a crucial level and could bounce hard. This simple option play could make 100% or more by July 21st. Stock is unloved by the market and is poised for a sharp rally on positive news. Those investors looking...
Share
Disney Channel, Gilead Sciences
The No. 1 Stock In The World (Revisited) - Apple Up, Realty Income Down
Seeking AlphaMike Nadel
Summary A two-year review of the May 2015 stock selections by a panel. Apple, beaten down in Year 1 of this collaborative project, had a heck of a comeback. Realty Income didn't fare as well in Year 2, but it still had...
Share
Finance, Gilead Sciences
Gilead's Dividend Stream Is Undervalued
Seeking AlphaAbba's Aces
Summary Gilead Sciences recently announced a quarterly dividend of $0.52 per share with an ex-dividend set for June 14th. The company hasn’t been increasing its dividend for a long time, so there isn’t much history to give investors a warm, fuzzy feeling....
Share
Gilead Sciences
Cramer's lightning round: I've got a message for the struggling Gilead Sciences
CNBC
Jim Cramer shares his take on caller favorite stocks, including this drugmaker.
Share
Gilead Sciences, Health Finance
Gilead Sciences' (GILD) Presents at Bank of America Merrill Lynch Healthcare Broker Conference Call (Transcript)
Seeking Alpha
Gilead Sciences, Inc. (NASDAQ:GILD) Bank of America Merrill Lynch Healthcare Broker Conference Call May 18, 2017, 12:20 ET Executives Sung Lee - VP, IR Kevin Young - COO Analysts Ying Huang - Bank of America Merrill Lynch Ying Huang I think we...
Share
Cancer, Gilead Sciences
Vantage Point - Are Charities The Best Way To Pay For Costly Drugs?
Seeking AlphaE.P. Vantage
When sales of its blockbuster prostate cancer drug Xtandi faltered last quarter, Pfizer (NYSE:PFE) pointed a finger at disruptions in charity care subsidies for low-income Medicare beneficiaries. While this could be read as reaching for a plausible explanation to defend a huge...
Share